Fig. 2From: Clusterin ameliorates tau pathology in vivo by inhibiting fibril formationLoss of Clusterin leads to behavioral abnormalities. a-b Behavioral and cognitive abilities were assessed using a the open field test (OFA) and b elevated plus maze (EPM) in CLU WT-GFP (N = 49), CLU KO-GFP (N = 12), CLU WT-TauP301L (N = 65), and CLU KO-TauP301L (N = 23). OFA was used to test anxiety-related behavior, evaluated by time spent in the center compared to total time travelled. EPM measured the time spent in the open arms during the test which is a reflection of exploratory behavior. Data present as mean ± S.E.M. and analyzed with two-way ANOVA with Fisher’s LSD test, *p < 0.05, **p < 0.01, ***p < 0.001Back to article page